Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma

Urology

Volumn 69, Issue 3, 2007, Pages 452-456

  Hollingsworth, John M ^a   Miller, David C ^a   Daignault, Stephanie ^a   Shah, Rajal B ^b   Hollenbeck, Brent K ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL FEATURE; DISEASE CLASSIFICATION; EVALUATION; HUMAN; INCIDENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; STANDARDIZATION; UNITED STATES;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LOGISTIC MODELS; ODDS RATIO; SEER PROGRAM; UNITED STATES;

EID: 33947280961     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.11.004     Document Type: Article

References (27)

1. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
2. Kovacs G., Akhtar M., Beckwith B.J., et al. The Heidelberg classification of renal cell tumours. J Pathol 183 (1997) 131-133
3. Amin M.B., Amin M.B., Tamboli P., et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26 (2002) 281-291
4. Beck S.D., Patel M.I., Snyder M.E., et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11 (2004) 71-77
5. Cheville J.C., Lohse C.M., Zincke H., et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 (2003) 612-624
6. Ljungberg B., Alamdari F.I., Stenling R., et al. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 36 (1999) 565-569
7. Moch H., Gasser T., Amin M.B., et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89 (2000) 604-614
8. Rini B.I., Sosman J.A., and Motzer R.J. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96 (2005) 286-290
9. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
10. Hankey B.F., Ries L.A., and Edwards B.K. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev 8 (1999) 1117-1121
11. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (2004), IARC Press, Lyon, France
12. Shah R.B., Bakshi N., Hafez K.S., et al. Image-guided biopsy in lesions in contemporary adequacy, clinical impact, pathological diagnosis. Hum Pathol 36 (2005) 1309-1315
13. Rybicki F.J., Shu K.M., Cibas E.S., et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 180 (2003) 1281-1287
14. Skinner D.G., Colvin R.B., Vermillion C.D., et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28 (1971) 1165-1177
15. Patard J.J., Leray E., Rioux-Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23 (2005) 2763-2771
16. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
17. Bukowski R.M. Immunotherapy in renal cell carcinoma. Oncology 13 (1999) 801-810
18. Figlin R.A. Renal cell carcinoma: management of advanced disease. J Urol 161 (1999) 381-386
19. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
20. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer (2005) Cochrane Database of Syst Rev No. CD001425
21. Rogers E. Diffusion of Innovations (1983), Free Press, New York
22. Lomas J. Words without action?. The production, dissemination, and impact of consensus recommendations. Annu Rev Public Health 12 (1991) 41-65
23. Lomas J., Anderson G.M., Domnick-Pierre K., et al. Do practice guidelines guide practice?. The effect of a consensus statement on the practice of physicians. N Engl J Med 321 (1989) 1306-1311
24. Bero L.A., Grilli R., Grimshaw J.M., et al., Cochrane Effective Practice and Organization of Care Review Group. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 317 (1998) 465-468
25. National Cancer Institute: SEER cancer statistics review, 1975-2002, 2005 update. Available at: http://seer.cancer.gov/csr/1975_2002/. Accessed April 30, 2006.
26. National Cancer Institute: The SEER coding and staging manual 2004, 2004 update. Available at: http://seer.cancer.gov/tools/codingmanuals/. Accessed April 30, 2006.
27. Field R.W., Smith B.J., Platz C.E., et al. Lung cancer histologic type in the Surveillance, Epidemiology, and End Results Registry versus independent review. J Natl Cancer Inst 96 (2004) 1105-1107